What is it about?
TARC is an extremely useful clinical biomarker for atopic dermatitis (AD) treatment. Serum TARC is a promising biomarker for accurately monitoring proactive treatment for long-term control. Abnormally high serum TARC levels indicate accelerated pathogenesis of cutaneous inflammation. Rapid normalization and maintaining normal serum TARC levels using appropriate topical treatment is a reasonable strategy for alleviating inflammation without upregulating cytokine expression.
Featured Image
Why is it important?
When the waning and waxing of eczema and fluctuations in the serum TARC levels were considered, we frequently found that AD does not follow a natural course but follows non-regulated inflammatory floating caused by insufficient intermittent topical treatment.
Perspectives
Dermatologists will be able to make great progress in treating AD by adopting biomarkers such as TARC for accurately assessing non-visible subclinical disorders.
MD YOKO KATAOKA
Osaka Habikino Medical Center
Read the Original
This page is a summary of: Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis, The Journal of Dermatology, March 2014, Wiley,
DOI: 10.1111/1346-8138.12440.
You can read the full text:
Contributors
The following have contributed to this page
